

# Chronic graft-versus-host disease and other late complications after transplantation

Seminars in Hematology

28, 250-9

Citation Report

#	ARTICLE	IF	CITATIONS
1	Bone marrow transplantation in sickle cell anaemia. <i>Blood Reviews</i> , 1993, 7, 1-3.	2.8	17
2	Bone Marrow Transplantation for Aplastic Anemia. <i>Cell Transplantation</i> , 1993, 2, 365-379.	1.2	26
3	Bone marrow and hemopoietic stem cell transplantation. <i>Acta Chirurgica Austriaca</i> , 1994, 26, 34-42.	0.2	0
4	Quality of life in adult bone marrow transplant patients: Beyond the first year. <i>Seminars in Oncology Nursing</i> , 1994, 10, 42-57.	0.7	38
5	Quality of life of 125 adults surviving 6â€“18 years after bone marrow transplantation. <i>Social Science and Medicine</i> , 1995, 40, 479-490.	1.8	176
6	BONE MARROW TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES AND CANCER. <i>Immunology and Allergy Clinics of North America</i> , 1996, 16, 393-427.	0.7	3
7	Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease. <i>Clinical and Experimental Immunology</i> , 2019, 104, 43-48.	1.1	17
8	Pulmonary Complications of Bone Marrow Transplantation. <i>Chest</i> , 1996, 109, 1066-1077.	0.4	330
9	Late infections following allogeneic bone marrow transplantation: Suggested strategies for prophylaxis. <i>Leukemia and Lymphoma</i> , 1997, 26, 1-15.	0.6	31
10	BONE MARROW TRANSPLANTATION FOR PEDIATRIC MALIGNANCIES. <i>Pediatric Clinics of North America</i> , 1997, 44, 1005-1020.	0.9	25
11	Umbilical cord blood stem cells: Application for the treatment of patients with hemoglobinopathies. <i>Journal of Pediatrics</i> , 1997, 130, 695-703.	0.9	35
12	Transplantation of Marrow Cells From Unrelated Donors for Treatment of High-Risk Acute Leukemia: The Effect of Leukemic Burden, Donor HLA-Matching, and Marrow Cell Dose. <i>Blood</i> , 1997, 89, 4226-4235.	0.6	358
13	Marrow Transplants From Unrelated Donors for Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 1997, 90, 1410-1414.	0.6	126
14	Hematopoietic stem cell transplants from unrelated donors. <i>Immunological Reviews</i> , 1997, 157, 141-151.	2.8	99
15	Late complications after bone marrow transplantation in children and adolescents. <i>Current Problems in Pediatrics</i> , 1998, 28, 277-297.	1.1	47
16	Treatment of oral chronic graft-versus-host disease with PUVA therapy. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 1998, 86, 183-187.	1.6	34
17	Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: A randomized, controlled trial. <i>Gastroenterology</i> , 1998, 115, 28-35.	0.6	81
18	Hematopoietic Stem Cell Transplantation. , 1998, , 1062-1070.		0

#	ARTICLE	IF	CITATIONS
19	Bone Marrow Transplants from Unrelated Donors for Patients with Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 1998, 338, 962-968.	13.9	602
20	T-Cell-Depleted Allogeneic Bone Marrow Transplantation as Postremission Therapy for Acute Myelogenous Leukemia: Freedom From Relapse in the Absence of Graft-Versus-Host Disease. <i>Blood</i> , 1998, 91, 1083-1090.	0.6	217
21	Update on Psychosocial Research on Leukaemia for Social Work Practitioners. <i>Social Work in Health Care</i> , 1999, 29, 1-20.	0.8	28
22	Opportunistic infections after blood and marrow transplantation. <i>Transplant Infectious Disease</i> , 1999, 1, 3-20.	0.7	62
23	New directions in leukaemia research: A focus on psychosocial issues from a consumers perspective. <i>Australian Social Work</i> , 1999, 52, 39-46.	0.7	11
24	CHOLESTASIS AFTER HEMATOPOIETIC CELL TRANSPLANTATION. <i>Clinics in Liver Disease</i> , 1999, 3, 651-668.	1.0	20
25	PATHOPHYSIOLOGY AND TREATMENT OF GRAFT-VERSUS-HOST DISEASE. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 1091-1112.	0.9	168
26	Bone Marrow Transplantation for Sickle Cell Disease. <i>Journal of Pediatric Hematology/Oncology</i> , 1999, 21, 467-474.	0.3	36
27	Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. <i>Bone Marrow Transplantation</i> , 2000, 26, 119-125.	1.3	73
28	Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. <i>Blood</i> , 2000, 96, 2055-2061.	0.6	480
29	Late Effects of Hematopoietic Stem Cell Transplantation. <i>Hematology</i> , 2000, 5, 209-222.	0.7	3
30	Additional Stem Cell Therapy for Graft Failure after Allogeneic Bone Marrow Transplantation. <i>Acta Haematologica</i> , 2000, 104, 185-192.	0.7	25
31	HLA matching in hematopoietic cell transplantation. <i>Human Immunology</i> , 2000, 61, 92-100.	1.2	32
32	Changes in the Periodontal Status of Patients Undergoing Bone Marrow Transplantation. <i>Journal of Periodontology</i> , 2000, 71, 394-402.	1.7	19
33	Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. <i>Cytotherapy</i> , 2001, 3, 41-54.	0.3	74
34	GASTROINTESTINAL INFECTIONS IN THE IMMUNOCOMPROMISED HOST. <i>Infectious Disease Clinics of North America</i> , 2001, 15, 639-670.	1.9	15
35	Preventing Opportunistic Infections After Hematopoietic Stem Cell Transplantation: The Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and Beyond. <i>Hematology American Society of Hematology Education Program</i> , 2001, 2001, 392-421.	0.9	123
36	Adhesion of MNC to extracellular matrix proteins following in vitro photochemotherapy. <i>Cytotherapy</i> , 2001, 3, 31-36.	0.3	0

#	ARTICLE	IF	CITATIONS
37	NONMYELOABLATIVE TRANSPLANTATION IN CHILDREN. <i>Hematology/Oncology Clinics of North America</i> , 2001, 15, 809-834.	0.9	10
38	Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. <i>Blood</i> , 2001, 97, 3390-3400.	0.6	1,306
39	How I treat chronic graft-versus-host disease. <i>Blood</i> , 2001, 97, 1196-1201.	0.6	232
40	Granulocyte colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. <i>Blood</i> , 2001, 98, 3186-3191.	0.6	167
41	Health and functional status of adult recipients 1 year after allogeneic haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2001, 113, 194-201.	1.2	50
42	New therapeutic modalities in the treatment of graft-versus-host disease. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 38, 129-138.	2.0	19
43	Rehabilitation following bone marrow transplantation. <i>Cancer</i> , 2001, 92, 998-1007.	2.0	34
44	A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2001, 28, 187-196.	1.3	76
45	Chronic graft-versus-host disease: clinical manifestation and therapy. <i>Bone Marrow Transplantation</i> , 2001, 28, 121-129.	1.3	219
46	Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2001, 28, 425-434.	1.3	264
47	Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2001, 28, 557-562.	1.3	34
48	Clinical importance of confirming or excluding the diagnosis of chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2001, 28, 1047-1051.	1.3	51
49	Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. <i>Experimental Hematology</i> , 2001, 29, 362-370.	0.2	93
50	Stem Cell Transplantation for Sickle Cell Disease: Can We Reduce the Toxicity?. <i>Fetal and Pediatric Pathology</i> , 2001, 20, 73-86.	0.3	5
51	Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. <i>Blood</i> , 2001, 98, 3569-3574.	0.6	252
52	Clinical Grading in Chronic Graft-Versus-Host Disease: Is it Time for Change?. <i>Leukemia and Lymphoma</i> , 2002, 43, 1211-1220.	0.6	13
53	Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. <i>Bone Marrow Transplantation</i> , 2002, 29, 817-823.	1.3	85
54	Ethical considerations on preimplantation genetic diagnosis for HLA typing to match a future child as a donor of haematopoietic stem cells to a sibling. <i>Human Reproduction</i> , 2002, 17, 534-538.	0.4	110

#	ARTICLE	IF	CITATIONS
55	Stem Cell Transplantation: Supportive Care and Long-Term Complications. Hematology American Society of Hematology Education Program, 2002, 2002, 422-444.	0.9	68
56	Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood, 2002, 100, 3128-3134.	0.6	174
57	Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood, 2002, 99, 2255-2258.	0.6	148
58	Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood, 2002, 100, 4358-4366.	0.6	911
59	Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood, 2002, 100, 2235-2242.	0.6	156
60	Supplemental peripheral blood stem cells to decrease marrow rejection in adult patients with severe aplastic anemia. American Journal of Hematology, 2002, 69, 15-22.	2.0	14
61	High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer, 2002, 95, 1076-1084.	2.0	155
62	Stem Cell Transplantation for Aplastic Anemia. International Journal of Hematology, 2002, 75, 141-146.	0.7	21
63	Chronic graft-versus-host disease and late effects after hematopoietic stem cell transplantation. International Journal of Hematology, 2002, 76, 15-28.	0.7	49
64	Extracorporeal Photochemotherapy for the Treatment of Graft-Versus-Host Disease. Therapeutic Apheresis and Dialysis, 2002, 6, 296-304.	0.4	117
65	CD34+ -enriched peripheral blood progenitor cells from unrelated donors for allografting of adult patients: high risk of graft failure, infection and relapse despite donor lymphocyte add-back. British Journal of Haematology, 2002, 118, 1095-1103.	1.2	24
66	Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplantation, 2002, 30, 189-194.	1.3	87
67	Flow cytometric findings in platelets of patients following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2002, 30, 381-387.	1.3	19
68	Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia, 2002, 16, 1423-1431.	3.3	103
69	Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies. Osteoporosis International, 2003, 14, 1013-1019.	1.3	52
70	Allogeneic hematopoietic cell transplantation for paroxysmal nocturnal hemoglobinuria. European Journal of Haematology, 2003, 71, 114-118.	1.1	24
71	Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimen. Experimental Hematology, 2003, 31, 873-880.	0.2	20
72	Steroid-refractory graft-vs.-host disease: past, present and future. Pediatric Transplantation, 2003, 7, 19-31.	0.5	26

#	ARTICLE	IF	CITATIONS
73	Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide for patients with hematologic malignancies. <i>International Journal of Laboratory Hematology</i> , 2003, 25, 383-391.	0.2	3
74	Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. <i>British Journal of Haematology</i> , 2003, 121, 411-418.	1.2	100
75	Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2003, 122, 118-127.	1.2	174
76	Graft-versus-host disease (GVHD)-specific survival and duration of systemic immunosuppressive treatment in patients who developed chronic GVHD following allogeneic haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2003, 122, 637-644.	1.2	21
77	Caregiver and patient marital satisfaction and affect following hematopoietic stem cell transplantation: a prospective, longitudinal investigation. <i>Psycho-Oncology</i> , 2003, 12, 239-253.	1.0	109
78	Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival. <i>Bone Marrow Transplantation</i> , 2003, 31, 175-181.	1.3	61
79	Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission: risk factors for long-term morbidity and mortality. <i>Bone Marrow Transplantation</i> , 2003, 31, 877-887.	1.3	28
80	High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma. <i>Bone Marrow Transplantation</i> , 2003, 32, 131-137.	1.3	22
81	Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Soci�t� Fran�saise de Greffe de Moelle et de Th�rapie Cellulaire (SFGM-TC). <i>Bone Marrow Transplantation</i> , 2003, 32, 993-999.	1.3	33
82	Late hemorrhagic cystitis after reduced-intensity hematopoietic stem cell transplantation (RIST). <i>Bone Marrow Transplantation</i> , 2003, 32, 1089-1095.	1.3	30
83	Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. <i>Leukemia</i> , 2003, 17, 869-875.	3.3	124
84	Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. <i>Leukemia</i> , 2003, 17, 2168-2177.	3.3	111
85	Chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 215-233.	2.0	801
86	Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 472-481.	2.0	75
87	Renal pathology at autopsy in patients who died after hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 683-688.	2.0	52
88	Hematopoietic cell transplantation from related and unrelated donors after minimal conditioning as a curative treatment modality for severe paroxysmal nocturnal hemoglobinuria. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 689-697.	2.0	46
89	Depletion of Host Reactive T Cells by Photodynamic Cell Purging and Prevention of Graft Versus Host Disease. <i>Leukemia and Lymphoma</i> , 2003, 44, 1871-1879.	0.6	10
90	Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. <i>Blood</i> , 2003, 102, 756-762.	0.6	531

#	ARTICLE	IF	CITATIONS
91	Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?. <i>Blood</i> , 2003, 101, 4233-4244.	0.6	262
92	Unrelated Donor Transplantation after Reduced Intensity Conditioning as an Approach for Patients Lacking Related Donors for Allogeneic Stem Cell Transplantation. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2003, 12, 331-339.	1.8	1
93	Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. <i>Blood</i> , 2003, 101, 1620-1629.	0.6	424
94	Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. <i>Blood</i> , 2003, 102, 3447-3454.	0.6	382
95	Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. <i>Blood</i> , 2003, 102, 802-809.	0.6	132
96	Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. <i>Blood</i> , 2003, 102, 820-826.	0.6	190
97	Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. <i>Blood</i> , 2003, 102, 470-476.	0.6	182
98	Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. <i>Blood</i> , 2003, 102, 827-833.	0.6	432
99	Fusarium Infection in Hematopoietic Stem Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2004, 38, 1237-1242.	2.9	300
100	Successful Engraftment After Reduced-Intensity Umbilical Cord Blood Transplantation for Adult Patients with Advanced Hematological Diseases. <i>Clinical Cancer Research</i> , 2004, 10, 3586-3592.	3.2	135
101	Breakthrough Fungal Infections in Stem Cell Transplant Recipients Receiving Voriconazole. <i>Clinical Infectious Diseases</i> , 2004, 39, 743-746.	2.9	395
102	Acute Renal Failure after Nonmyeloablative Hematopoietic Cell Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 1868-1876.	3.0	84
103	Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. <i>Transplant Infectious Disease</i> , 2004, 6, 110-116.	0.7	125
104	Chronic graft versus host disease. <i>British Journal of Haematology</i> , 2004, 125, 435-454.	1.2	145
105	Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor. <i>Bone Marrow Transplantation</i> , 2004, 33, 697-702.	1.3	21
106	Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies. <i>Bone Marrow Transplantation</i> , 2004, 33, 891-900.	1.3	25
107	Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies. <i>Bone Marrow Transplantation</i> , 2004, 33, 1123-1129.	1.3	25
108	Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2004, 34, 77-84.	1.3	66

#	ARTICLE	IF	CITATIONS
109	A prospective study of health-related quality of life, fatigue, anxiety and depression 3â€“5 years after stem cell transplantation. Bone Marrow Transplantation, 2004, 34, 257-266.	1.3	139
110	Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. Bone Marrow Transplantation, 2004, 34, 309-316.	1.3	26
111	Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes. Bone Marrow Transplantation, 2004, 34, 425-431.	1.3	23
112	Transplantation of unrelated placental blood cells in children with high-risk sickle cell disease. Bone Marrow Transplantation, 2004, 34, 405-411.	1.3	38
113	Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplantation, 2004, 34, 505-509.	1.3	116
114	Regimen-related toxicity following reduced-intensity stem-cell transplantation (RIST): comparison between Seattle criteria and National Cancer Center Common Toxicity Criteria (NCI-CTC) version 2.0. Bone Marrow Transplantation, 2004, 34, 787-794.	1.3	14
115	Chronic Graft-versus-Host Disease: Clinical Features and Grading Systems. International Journal of Hematology, 2004, 79, 216-220.	0.7	12
116	Unrelated Cord Blood Transplantation with a Reduced-Intensity Conditioning Regimen following Autologous Transplantation for Multiple Myeloma. International Journal of Hematology, 2004, 80, 377-380.	0.7	8
117	Long term follow-up of Asian patients with chronic myeloid leukemia (CML) receiving allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical sibling?evaluation of risks and benefits. Annals of Hematology, 2004, 83, 286-294.	0.8	9
118	Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood, 2004, 103, 1527-1533.	0.6	414
119	Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biology of Blood and Marrow Transplantation, 2004, 10, 494-503.	2.0	132
120	Incidence of invasive aspergillosis after allogeneic hematopoietic stem cell transplantation with a reduced-intensity regimen compared with transplantation with a conventional regimen. Biology of Blood and Marrow Transplantation, 2004, 10, 645-652.	2.0	36
121	New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood, 2004, 104, 1201-1203.	0.6	182
122	Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood, 2004, 104, 961-968.	0.6	300
123	Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood, 2004, 104, 1550-1558.	0.6	299
124	Early Immune Reaction after Reduced-Intensity Cord-Blood Transplantation for Adult Patients. Transplantation, 2005, 80, 34-40.	0.5	102
125	Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood, 2005, 105, 4115-4119.	0.6	194
126	Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor I <sup>2</sup> genotype of donor. Blood, 2005, 106, 3995-4001.	0.6	74



#	ARTICLE	IF	CITATIONS
127	Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <i>Blood</i> , 2005, 106, 3314-3321.	0.6	67
128	Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. <i>Blood</i> , 2005, 106, 3308-3313.	0.6	99
129	Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. <i>Blood</i> , 2005, 106, 2912-2919.	0.6	2,427
130	Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. <i>Leukemia Research</i> , 2005, 29, 961-966.	0.4	56
131	Cytomegalovirus infection after allogeneic stem cell transplant in children. <i>Pediatric Transplantation</i> , 2005, 9, 734-740.	0.5	27
132	Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2005, 129, 381-391.	1.2	41
133	Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors. <i>British Journal of Haematology</i> , 2005, 129, 795-802.	1.2	16
134	Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. <i>British Journal of Haematology</i> , 2005, 130, 394-403.	1.2	110
135	Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors. <i>British Journal of Haematology</i> , 2005, 130, 575-587.	1.2	38
136	Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: The Pediatric Blood and Marrow Transplant Consortium Experience (PBMTC) 1996-2003. <i>Bone Marrow Transplantation</i> , 2005, 35, 361-367.	1.3	96
137	Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning. <i>Bone Marrow Transplantation</i> , 2005, 35, 277-282.	1.3	41
138	Medium dose long-wavelength ultraviolet A (LVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. <i>Bone Marrow Transplantation</i> , 2005, 35, 515-519.	1.3	66
139	Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. <i>Bone Marrow Transplantation</i> , 2005, 36, 205-213.	1.3	46
140	Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2005, 36, 621-629.	1.3	117
141	Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. <i>Bone Marrow Transplantation</i> , 2005, 36, 963-969.	1.3	53
142	CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. <i>Experimental Hematology</i> , 2005, 33, 279-285.	0.2	43
143	Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. <i>Cancer</i> , 2005, 104, 1931-1938.	2.0	56
144	Pulmonary complications following hematopoietic stem cell transplantation: Diagnostic approaches. <i>American Journal of Hematology</i> , 2005, 80, 137-146.	2.0	29

#	ARTICLE	IF	CITATIONS
145	Development, feasibility and compliance of a web-based system for very frequent QOL and symptom home self-assessment after hematopoietic stem cell transplantation. <i>Quality of Life Research</i> , 2005, 14, 77-93.	1.5	60
146	Late Gastrointestinal and Hepatic Effects. , 2005, , 181-202.		5
147	Manifestações tegumentares da doença enxerto contra hospedeiro em pacientes transplantados de medula óssea. <i>Anais Brasileiros De Dermatologia</i> , 2005, 80, 69-80.	0.5	10
148	Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 85-92.	2.0	54
149	Bloodstream Infection after Umbilical Cord Blood Transplantation Using Reduced-Intensity Stem Cell Transplantation for Adult Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 429-436.	2.0	58
150	Reduced-Intensity Conditioning Allogeneic Blood Stem Cell Transplantation with Fludarabine and Oral Busulfan with or without Pharmacokinetically Targeted Busulfan Dosing in Patients with Myeloid Leukemia Ineligible for Conventional Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 437-447.	2.0	26
151	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 945-956.	2.0	3,213
152	Life-threatening graft-vs-host disease. <i>Clinics in Dermatology</i> , 2005, 23, 285-300.	0.8	40
153	Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity setting. <i>Transplant Immunology</i> , 2005, 15, 173-177.	0.6	7
154	Scoring system for monitoring oral lichenoid lesions: A preliminary study. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2005, 99, 696-703.	1.6	93
155	The Lung as a Target Organ of Graft-Versus-Host Disease. <i>Seminars in Hematology</i> , 2006, 43, 42-52.	1.8	57
156	Chronic Graft-Versus-Host Disease. <i>Drugs</i> , 2006, 66, 1041-1057.	4.9	71
157	Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. <i>Blood</i> , 2006, 107, 3065-3073.	0.6	482
158	Severe Infections after Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation in Adults: Comparison of Cord Blood Transplantation with Peripheral Blood and Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 734-748.	2.0	180
159	Association of Mixed Hematopoietic Chimerism with Elevated Circulating Autoantibodies and Chronic Graft-versus-Host Disease Occurrence. <i>Transplantation</i> , 2006, 81, 573-582.	0.5	25
160	Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2006, 135, 201-209.	1.2	56
161	Risk and prognostic factors for Japanese patients with chronic graft-versus-host disease after bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2006, 37, 289-296.	1.3	30
162	Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2006, 38, 477-482.	1.3	22

#	ARTICLE	IF	CITATIONS
163	Chronic graft-versus-host disease. <i>Blood Reviews</i> , 2006, 20, 15-27.	2.8	123
164	Different $\hat{T}^3/\hat{T}^4$ T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation. <i>Leukemia Research</i> , 2006, 30, 529-535.	0.4	14
165	Stable Engraftment after a Conditioning Regimen with Fludarabine and Melphalan for Bone Marrow Transplantation from an Unrelated Donor. <i>International Journal of Hematology</i> , 2006, 83, 356-362.	0.7	15
166	Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation. <i>Annals of Hematology</i> , 2006, 85, 113-120.	0.8	24
167	Cord blood transplantation for acute myelogenous leukemia using a conditioning regimen consisting of granulocyte colony-stimulating factor-combined high-dose cytarabine, fludarabine, and total body irradiation. <i>European Journal of Haematology</i> , 2006, 77, 46-50.	1.1	13
168	Cryptozoospermia with normal testicular function after allogeneic stem cell transplantation: A Case Report. <i>Human Reproduction</i> , 2007, 22, 495-499.	0.4	9
169	A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma. <i>New England Journal of Medicine</i> , 2007, 356, 1110-1120.	13.9	479
170	The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. <i>Blood</i> , 2007, 109, 1782-1789.	0.6	126
171	Extracorporeal Photopheresis for Steroid Resistant Graft Versus Host Disease in Pediatric Patients. <i>Journal of Pediatric Hematology/Oncology</i> , 2007, 29, 678-687.	0.3	50
172	Prediction of Nonrelapse Mortality for Patients Surviving 100 Days After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation Proceedings</i> , 2007, 39, 3375-3379.	0.3	6
173	Transplant-Associated Microangiopathy in Patients Receiving Tacrolimus Following Allogeneic Stem Cell Transplantation: Risk Factors and Response to Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 469-477.	2.0	64
174	Cytomegalovirus Infections following Umbilical Cord Blood Transplantation Using Reduced Intensity Conditioning Regimens for Adult Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 577-583.	2.0	65
175	Impact of Postgrafting Immunosuppressive Regimens on Nonrelapse Mortality and Survival after Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant Using the Fludarabine and Low-Dose Total-Body Irradiation 200-cGy. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 790-805.	2.0	10
176	Comparable Antileukemia/Lymphoma Effects in Nonremission Patients Undergoing Allogeneic Hematopoietic Cell Transplantation with a Conventional Cytoablative or Reduced-Intensity Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 932-941.	2.0	28
177	CD3+ Cell Dose and Disease Status Are Important Factors Determining Clinical Outcomes in Patients Undergoing Unmanipulated Haploidentical Blood and Marrow Transplantation after Conditioning Including Antithymocyte Globulin. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1515-1524.	2.0	34
178	Long-term follow-up of Asian patients younger than 46 years with acute myeloid leukemia in first complete remission: comparison of allogeneic vs. autologous hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2007, 48, 72-79.	0.6	7
179	Unrelated donor bone marrow transplantation using a chemotherapy-only preparative regimen for adults with high-risk acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2007, 82, 6-14.	2.0	8
180	Facilitating cells: Novel promoters of stem cell alloengraftment and donor-specific transplantation tolerance in the absence of GVHD. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 61, 26-43.	2.0	20

#	ARTICLE	IF	CITATIONS
181	Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults. <i>Bone Marrow Transplantation</i> , 2007, 39, 31-39.	1.3	66
182	The influence of cyclosporin alone, or cyclosporin and methotrexate, on the incidence of mixed haematopoietic chimaerism following allogeneic sibling bone marrow transplantation for severe aplastic anaemia. <i>Bone Marrow Transplantation</i> , 2007, 39, 109-114.	1.3	28
183	New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. <i>Bone Marrow Transplantation</i> , 2007, 40, 541-547.	1.3	65
184	Intensive postgrafting immune suppression combined with nonmyeloablative conditioning for transplantation of HLA-identical hematopoietic cell grafts: results of a pilot study for treatment of primary immunodeficiency disorders. <i>Bone Marrow Transplantation</i> , 2007, 40, 633-642.	1.3	38
185	Chronic graft-versus-host disease in the era of reduced-intensity conditioning. <i>Leukemia</i> , 2007, 21, 853-859.	3.3	28
186	Anesthesia and graft-vs-host disease after hematopoietic stem cell transplantation. <i>Paediatric Anaesthesia</i> , 2007, 17, 7-15.	0.6	4
187	Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. <i>British Journal of Haematology</i> , 2007, 137, 142-151.	1.2	61
188	Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoietic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. <i>British Journal of Haematology</i> , 2007, 138, 517-526.	1.2	39
189	Mucosal graft-versus-host disease. <i>Oral Diseases</i> , 2007, 13, 519-529.	1.5	17
190	Serologically HLA-DR mismatched Unrelated Donors Might Provide a Valuable Alternative in Allogeneic Transplantation: Experience from a Single Japanese Institution. <i>International Journal of Hematology</i> , 2007, 85, 163-169.	0.7	4
191	Unrelated-Donor Bone Marrow Transplantation with a Conditioning Regimen Including Fludarabine, Busulfan, and 4 Gy Total Body Irradiation. <i>International Journal of Hematology</i> , 2007, 85, 256-263.	0.7	11
192	Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2007, 86, 275-281.	0.7	11
193	Postmortem examination of the kidney in allogeneic hematopoietic stem cell transplantation recipients: possible involvement of graft-versus-host disease. <i>International Journal of Hematology</i> , 2008, 87, 225-230.	0.7	30
194	Allogeneic stem cell transplantation for refractory adult T-cell leukemia using a non-T-cell-depleted HLA-incompatible family donor graft, with reference to the grown-up child donor to parent recipient setting: report of a pilot study. <i>International Journal of Hematology</i> , 2008, 87, 319-326.	0.7	6
195	Reduced-intensity unrelated donor bone marrow transplantation for hematologic malignancies. <i>International Journal of Hematology</i> , 2008, 88, 324-330.	0.7	5
196	Long-term results of survival in patients with thalassemia major treated with bone marrow transplantation. <i>American Journal of Hematology</i> , 2008, 83, 528-530.	2.0	70
197	Characterization of acute graft-versus-host disease following reduced-intensity stem cell transplantation from an HLA-identical related donor. <i>American Journal of Hematology</i> , 2008, 83, 630-634.	2.0	3
198	Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV-seropositive recipients and donors. <i>American Journal of Hematology</i> , 2008, 83, 649-653.	2.0	18

#	ARTICLE	IF	CITATIONS
199	Quantitative analysis of Langerhansâ€™ cells in oral chronic graft-versus-host disease. <i>Journal of Oral Pathology and Medicine</i> , 2009, 38, 132-137.	1.4	9
200	Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?. <i>Bone Marrow Transplantation</i> , 2008, 41, 935-940.	1.3	31
201	Extracorporeal photochemotherapy may improve outcome in children with acute GVHD. <i>Bone Marrow Transplantation</i> , 2008, 42, 421-425.	1.3	65
202	Cell cycle and immune-related processes are significantly altered in chronic GVHD. <i>Bone Marrow Transplantation</i> , 2008, 41, 1047-1057.	1.3	11
203	Clinical characteristics of chronic graft-versus-host disease following umbilical cord blood transplantation for adults. <i>Bone Marrow Transplantation</i> , 2008, 41, 729-736.	1.3	5
204	Relation of an interleukin-23 receptor gene polymorphism to graft-versus-host disease after hematopoietic-cell transplantation. <i>Bone Marrow Transplantation</i> , 2008, 41, 821-826.	1.3	64
205	Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens. <i>Bone Marrow Transplantation</i> , 2008, 41, 887-893.	1.3	18
206	Nonâ€™myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large Bâ€™cell lymphoma: a multicentre experience. <i>British Journal of Haematology</i> , 2008, 143, 395-403.	1.2	97
207	GVHD pathophysiology: is acute different from chronic?. <i>Best Practice and Research in Clinical Haematology</i> , 2008, 21, 101-117.	0.7	71
208	Diagnosis and manifestations of chronic graft-versus-host disease. <i>Best Practice and Research in Clinical Haematology</i> , 2008, 21, 251-257.	0.7	96
209	Prevention of chronic GVHD. <i>Best Practice and Research in Clinical Haematology</i> , 2008, 21, 259-270.	0.7	14
210	Long-Term Outcome after Bone Marrow Transplantation for Aplastic Anemia Using Cyclophosphamide and Total Lymphoid Irradiation as Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 43-49.	2.0	21
211	Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched Related Donor. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 282-289.	2.0	119
212	HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 641-650.	2.0	1,525
213	Impact of T Cell Chimerism on Clinical Outcome in 117 Patients Who Underwent Allogeneic Stem Cell Transplantation with a Busulfan-Containing Reduced-Intensity Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1148-1155.	2.0	40
214	Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1279-1287.	2.0	251
215	Oral Graft-Versus-Host Disease. <i>Dental Clinics of North America</i> , 2008, 52, 79-109.	0.8	121
216	Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2008, 14, 5585-5593.	3.2	26

#	ARTICLE	IF	CITATIONS
217	T cell receptor excision circle levels in CD94-expressing CD8 T Cells during graft-versus-host disease. <i>Leukemia and Lymphoma</i> , 2008, 49, 1306-1310.	0.6	2
218	Toll-like Receptor 4 Polymorphisms and Aspergillosis in Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2008, 359, 1766-1777.	13.9	408
220	Chronic graft-versus-host disease following umbilical cord blood transplantation: retrospective survey involving 1072 patients in Japan. <i>Blood</i> , 2008, 112, 2579-2582.	0.6	40
221	Infection prevention strategies in a stem cell transplant unit: impact of change of care in isolation practice and routine use of high dose intravenous immunoglobulins on infectious complications and transplant related mortality. <i>European Journal of Haematology</i> , 2009, 83, 130-138.	1.1	10
222	Invasive Fungal Infection in Haematopoietic Stem Cell Transplant Recipients: Epidemiology from the Transplant Physician's Viewpoint. <i>Mycopathologia</i> , 2009, 168, 283-297.	1.3	37
223	Expression of CD62L on Donor CD4+ T Cells in Allografts: Correlation with Graft-Versus-Host Disease after Unmanipulated Allogeneic Blood and Marrow Transplantation. <i>Journal of Clinical Immunology</i> , 2009, 29, 696-704.	2.0	20
224	Mycophenolate mofetil combined with tacrolimus and minidose methotrexate after unrelated donor bone marrow transplantation with reduced-intensity conditioning. <i>International Journal of Hematology</i> , 2009, 89, 538-545.	0.7	8
225	The impact of CD34 <sup>+</sup> cell dose on platelet engraftment in pediatric patients following unmanipulated haploidentical blood and marrow transplantation. <i>Pediatric Blood and Cancer</i> , 2009, 53, 1100-1106.	0.8	21
226	Feasibility of NIH consensus criteria for chronic graft-versus-host disease. <i>Leukemia</i> , 2009, 23, 78-84.	3.3	101
227	Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. <i>Leukemia</i> , 2009, 23, 635-640.	3.3	72
228	Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil. <i>Modern Pathology</i> , 2009, 22, 737-743.	2.9	151
229	Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients. <i>Bone Marrow Transplantation</i> , 2009, 44, 35-41.	1.3	31
230	Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy. <i>Bone Marrow Transplantation</i> , 2009, 44, 43-49.	1.3	64
231	Improved outcome of hematopoietic SCT in patients with homozygous gene variant of Toll-like receptor 9. <i>Bone Marrow Transplantation</i> , 2009, 44, 295-302.	1.3	29
232	Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. <i>Bone Marrow Transplantation</i> , 2009, 44, 361-370.	1.3	126
233	Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. <i>Bone Marrow Transplantation</i> , 2009, 44, 739-748.	1.3	84
234	High complete remission rate and durable remissions achieved with rational use of autologous stem cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma. <i>Clinical Transplantation</i> , 2009, 23, 839-847.	0.8	2
235	Iron overload in survivors of childhood leukemia after allogeneic hematopoietic stem cell transplantation. <i>Pediatric Transplantation</i> , 2009, 13, 348-352.	0.5	31

#	ARTICLE	IF	CITATIONS
236	Blood Stream Infections in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Reemergence of Gram-Negative Rods and Increasing Antibiotic Resistance. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 47-53.	2.0	189
237	Prolonged Chronic Graft-versus-Host Disease is a Risk Factor for Thyroid Failure in Long-Term Survivors After Matched Sibling Donor Stem Cell Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 377-381.	2.0	35
238	Platelet Engraftment in Patients with Hematologic Malignancies following Unmanipulated Haploidentical Blood and Marrow Transplantation: Effects of CD34+ Cell Dose and Disease Status. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 632-638.	2.0	63
239	Regimen-Related Mucosal Injury of the Gut Increased the Incidence of CMV Disease after Allogeneic Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 679-685.	2.0	7
240	Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 694-703.	2.0	70
241	Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Antithymocyte Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1422-1430.	2.0	89
242	Race and Socioeconomic Status Influence Outcomes of Unrelated Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1543-1554.	2.0	135
243	Polymorphism of Interleukin-23 Receptor Gene But Not of NOD2/CARD15 Is Associated with Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation in Children. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1571-1577.	2.0	49
244	HLA-haploidentical blood and bone marrow transplantation with anti-thymocyte globulin: Long-term comparison with HLA-identical sibling transplantation. <i>Blood Cells, Molecules, and Diseases</i> , 2009, 43, 98-104.	0.6	43
245	Emergencies Related to Cancer Chemotherapy and Hematopoietic Stem Cell Transplantation. <i>Emergency Medicine Clinics of North America</i> , 2009, 27, 311-331.	0.5	22
246	Graft-versus-host disease. <i>Lancet, The</i> , 2009, 373, 1550-1561.	6.3	2,093
247	IL10 and IL10 Receptor Gene Variation and Outcomes After Unrelated and Related Hematopoietic Cell Transplantation. <i>Transplantation</i> , 2009, 87, 704-710.	0.5	27
248	Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab. <i>Haematologica</i> , 2009, 94, 956-966.	1.7	32
249	Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. <i>Blood</i> , 2009, 113, 3375-3382.	0.6	92
250	Impact of HLA disparity in the graft-versus-host direction on engraftment in adult patients receiving reduced-intensity cord blood transplantation. <i>Blood</i> , 2009, 114, 1689-1695.	0.6	44
251	Hematopoietic stem cell transplantation for children with sickle cell disease. , 2009, , CD007001.		13
252	Impact of donor characteristics in survival and graft-versus-host disease following pediatric hematopoietic stem cell transplant. <i>Pediatric Health</i> , 2009, 3, 181-189.	0.3	0
253	Graft-versus-host disease-related polymyositis. <i>Clinical Rheumatology</i> , 2010, 29, 431-433.	1.0	15

#	ARTICLE	IF	CITATIONS
254	Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation. <i>International Journal of Hematology</i> , 2010, 91, 310-321.	0.7	0
255	Serum HO-1 is useful to make differential diagnosis of secondary hemophagocytic syndrome from other similar hematological conditions. <i>International Journal of Hematology</i> , 2010, 91, 229-237.	0.7	14
256	Hematopoietic stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia: a single-center analysis of 47 patients. <i>International Journal of Hematology</i> , 2010, 92, 334-341.	0.7	7
257	<sup>188</sup> Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and <i>in vivo</i> T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2010, 148, 910-917.	1.2	21
258	Donor single nucleotide polymorphism in the CCR9 gene affects the incidence of skin GVHD. <i>Bone Marrow Transplantation</i> , 2010, 45, 363-369.	1.3	23
259	Eosinophilia predicts better overall survival after acute graft-versus-host-disease. <i>Bone Marrow Transplantation</i> , 2010, 45, 371-377.	1.3	18
260	Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. <i>Bone Marrow Transplantation</i> , 2010, 45, 458-463.	1.3	141
261	Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. <i>Bone Marrow Transplantation</i> , 2010, 45, 429-436.	1.3	57
262	Impact on relapse of corticosteroid therapy after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. <i>Clinical Transplantation</i> , 2010, 24, 772-777.	0.8	5
263	Increased risk of bacterial infection after engraftment in patients treated with allogeneic bone marrow transplantation following reduced-intensity conditioning regimen. <i>Transplant Infectious Disease</i> , 2010, 12, 412-420.	0.7	13
264	Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide. <i>The Korean Journal of Hematology</i> , 2010, 45, 102.	0.7	12
265	Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. <i>Blood</i> , 2010, 116, 1369-1376.	0.6	255
266	Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Haematologica</i> , 2010, 95, 983-988.	1.7	64
267	The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. <i>Bone Marrow Transplantation</i> , 2010, 45, 1587-1593.	1.3	64
268	UVA (UVA-1) therapy for the treatment of acute GVHD of the skin. <i>Bone Marrow Transplantation</i> , 2010, 45, 1741-1748.	1.3	28
269	Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience. <i>Bone Marrow Transplantation</i> , 2010, 45, 1502-1507.	1.3	51
270	Suicide gene therapy for graft-versus-host disease. <i>Immunotherapy</i> , 2010, 2, 521-537.	1.0	5
271	Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins. <i>Expert Review of Hematology</i> , 2010, 3, 633-651.	1.0	3



#	ARTICLE	IF	CITATIONS
272	Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 1000-1005.	1.5	61
273	Association of HMGB1 Polymorphisms with Outcome after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 239-252.	2.0	49
274	The Effect of the Composition of Unrelated Donor Bone Marrow and Peripheral Blood Progenitor Cell Grafts on Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 253-262.	2.0	28
275	Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I-Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients with Hematologic Malignancies: A Multicenter Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 384-394.	2.0	39
276	Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 555-559.	2.0	46
277	Tumor Necrosis Factor- $\beta$ Gene Polymorphisms Are Associated with Severity of Acute Graft-Versus-Host Disease Following Matched Unrelated Donor Bone Marrow Transplantation in Children: A Pediatric Blood and Marrow Transplant Consortium Study. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 927-936.e1.	2.0	21
278	Unrelated Transplantation for Poor-Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Outcome Analysis and Study of the Impact of Hematopoietic Graft Source. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 957-966.	2.0	35
279	Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: Role of the Conditioning Regimen and the Type of Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 985-993.	2.0	109
280	Favorable Outcomes in Patients Surviving 5 or More Years after Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1162-1170.	2.0	32
281	Gene Expression Profiling-Based Identification of CD28 and PI3K as New Biomarkers for Chronic Graft-Versus-Host Disease. <i>DNA and Cell Biology</i> , 2011, 30, 1019-1025.	0.9	12
282	Evolution of the donor T-cell repertoire in recipients in the second decade after allogeneic stem cell transplantation. <i>Blood</i> , 2011, 117, 5250-5256.	0.6	18
283	Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350) Tj ETQq1 1 0.784314 rgBT <sub>32</sub> /Overlock	2.0	32
284	Immune Reactions following Cord Blood Transplantations in Adults. <i>Stem Cells International</i> , 2011, 2011, 1-6.	1.2	5
285	Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti- $\alpha$ T-cell globulin ATG-Fresenius. <i>Blood</i> , 2011, 117, 6375-6382.	0.6	281
286	Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2011, 4, 149-156.	0.6	9
287	Comparison of reduced intensity and myeloablative conditioning regimens for stem cell transplantation in patients with malignancies: a meta-analysis. <i>Clinical Transplantation</i> , 2011, 25, E187-98.	0.8	11
288	Increased activity and improved outcome in unrelated donor haemopoietic cell transplants for acute myeloid leukaemia in Australia, 1992-2005. <i>Internal Medicine Journal</i> , 2011, 41, 27-34.	0.5	6
289	Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein. <i>Leukemia</i> , 2011, 25, 629-637.	3.3	27

#	ARTICLE	IF	CITATIONS
290	Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation. <i>International Journal of Hematology</i> , 2011, 93, 509-516.	0.7	8
291	Outcome of medium-dose VP-16/CY/TBI superior to CY/TBI as a conditioning regimen for allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia. <i>International Journal of Hematology</i> , 2011, 94, 463-471.	0.7	15
292	Clinical impact of absolute lymphocyte count on day 30 after unmanipulated haploidentical blood and marrow transplantation for pediatric patients with hematological malignancies. <i>American Journal of Hematology</i> , 2011, 86, 227-230.	2.0	18
293	Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. <i>Hematological Oncology</i> , 2011, 29, 202-210.	0.8	14
294	A prospective dose-finding trial using a modified continual reassessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors in patients with hematopoietic malignancies. <i>Annals of Oncology</i> , 2011, 22, 1865-1871.	0.6	10
295	Tacrolimus and mycophenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases. <i>Bone Marrow Transplantation</i> , 2011, 46, 747-755.	1.3	11
296	Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis. <i>Bone Marrow Transplantation</i> , 2011, 46, 557-561.	1.3	19
297	Long-term follow-up of a pilot study using a chemotherapy-alone protocol for killer Ig-like receptor-ligand-mismatched haploidentical haematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2011, 46, 1331-1338.	1.3	5
298	Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. <i>Blood</i> , 2011, 118, 2351-2357.	0.6	148
299	Toll-like receptor 9, NOD2 and IL23R gene polymorphisms influenced outcome in AML patients transplanted from HLA-identical sibling donors. <i>Bone Marrow Transplantation</i> , 2011, 46, 702-708.	1.3	27
300	Disease stage stratified effects of cell dose in unrelated BMT for hematological malignancies: a report from Japan marrow donor program. <i>Bone Marrow Transplantation</i> , 2011, 46, 1192-1202.	1.3	5
301	Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. <i>Bone Marrow Transplantation</i> , 2012, 47, 494-498.	1.3	59
302	Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2012, 47, 700-705.	1.3	24
303	Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options. <i>Bone Marrow Transplantation</i> , 2012, 47, 1020-1029.	1.3	42
304	Single center retrospective analysis of BU-based conditioning regimens in allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2012, 47, 181-189.	1.3	2
305	Clinical significance of hemophagocytosis in BM clot sections during the peri-engraftment period following allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2012, 47, 387-394.	1.3	16
306	Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. <i>Leukemia and Lymphoma</i> , 2012, 53, 901-906.	0.6	20
307	Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease. <i>Haematologica</i> , 2012, 97, 717-722.	1.7	22

#	ARTICLE	IF	CITATIONS
308	Younger donor's age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: a retrospective study from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). <i>Haematologica</i> , 2012, 97, 482-490.	1.7	10
309	Eosinophilia, Regardless of Degree, is Related to Better Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Internal Medicine</i> , 2012, 51, 851-858.	0.3	2
310	Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. <i>Blood</i> , 2012, 119, 2141-2148.	0.6	110
311	Related transplantation with HLA-1 Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation: a nationwide retrospective study. <i>Blood</i> , 2012, 119, 2409-2416.	0.6	57
312	Toll-Like 4 Receptor Variant, Asp299Gly, and Reduced Risk of Hemorrhagic Cystitis after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 958-963.	2.0	6
313	Extensive Dental Caries in Patients with Oral Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1573-1579.	2.0	39
314	Multicenter Experience Using Total Lymphoid Irradiation and Antithymocyte Globulin as Conditioning for Allografting in Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1600-1607.	2.0	25
315	The role of the extracorporeal photopheresis in the management of the graft-versus-host disease. <i>Transfusion and Apheresis Science</i> , 2012, 46, 211-219.	0.5	11
316	The incidence and risk factors of invasive fungal infection after haploidentical haematopoietic stem cell transplantation without in vitro T-cell depletion. <i>Clinical Microbiology and Infection</i> , 2012, 18, 997-1003.	2.8	29
317	Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 617-626.	2.0	75
318	Relationship of Race/Ethnicity and Survival after Single Umbilical Cord Blood Transplantation for Adults and Children with Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 903-912.	2.0	43
319	Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis. <i>Haematologica</i> , 2012, 97, 1574-1581.	1.7	59
320	Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. <i>Leukemia Research</i> , 2012, 36, 1147-1151.	0.4	43
321	Immune Recovery in Adult Patients after Myeloablative Dual Umbilical Cord Blood, Matched Sibling, and Matched Unrelated Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1664-1676.e1.	2.0	94
322	Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1835-1844.	2.0	227
323	Extracorporeal photopheresis: Clinical use so far. <i>Journal of Clinical Apheresis</i> , 2012, 27, 126-131.	0.7	15
324	Immune Reconstitution Following Unmanipulated HLA-Mismatched/Haploidentical Transplantation Compared with HLA-Identical Sibling Transplantation. <i>Journal of Clinical Immunology</i> , 2012, 32, 268-280.	2.0	81
325	Single-institution long-term outcomes for patients receiving nonmyeloablative conditioning hematopoietic cell transplantation for chronic lymphocytic leukemia and follicular lymphoma. <i>European Journal of Haematology</i> , 2012, 89, 151-159.	1.1	6

#	ARTICLE	IF	CITATIONS
326	Success of allogeneic marrow transplantation for children with severe aplastic anaemia. <i>British Journal of Haematology</i> , 2012, 158, 120-128.	1.2	23
327	Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2012, 91, 577-586.	0.8	17
328	Lack of association of platelet-derived growth factor (PDGF) receptor autoantibodies and severity of chronic graft-versus-host disease (GvHD). <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1397-1404.	1.2	13
329	Differing impacts of pretransplant serum ferritin and C-reactive protein levels on the incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2013, 97, 109-116.	0.7	23
330	Unrelated cord blood transplantation for central nervous system relapse in high-risk childhood acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2013, 92, 1665-1673.	0.8	5
331	Impact of Graft-versus-Host Disease on Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Leukemia-Lymphoma Focusing on Preconditioning Regimens: Nationwide Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1731-1739.	2.0	46
332	Similar Overall Survival Using Sibling, Unrelated Donor, and Cord Blood Grafts after Reduced-Intensity Conditioning for Older Patients with Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1355-1360.	2.0	81
333	Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. <i>Leukemia Research</i> , 2013, 37, 1482-1487.	0.4	2
334	Nonrelapse Mortality and Mycophenolic Acid Exposure in Nonmyeloablative Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1159-1166.	2.0	29
335	Impact of the Direction of HLA Mismatch on Transplantation Outcomes in Single Unrelated Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 247-254.	2.0	46
336	Unrelated cord blood transplantation vs related transplantation with HLA 1-antigen mismatch in the graft-versus-host direction. <i>Leukemia</i> , 2013, 27, 286-294.	3.3	31
337	Hematopoietic stem cell transplantation for people with sickle cell disease. , 2013, , CD007001.		4
338	The significant impact of acute kidney injury on CKD in patients who survived over 10 years after myeloablative allogeneic SCT. <i>Bone Marrow Transplantation</i> , 2013, 48, 80-84.	1.3	42
339	Allo-SCT for multiple myeloma in the era of novel agents: a retrospective study on behalf of Swiss Blood SCT. <i>Bone Marrow Transplantation</i> , 2013, 48, 408-413.	1.3	6
340	Reduced-intensity allogeneic stem cell transplantation for patients aged 50 years or older with B-cell ALL in remission: a retrospective study by the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation. <i>Bone Marrow Transplantation</i> , 2013, 48, 1513-1518.	1.3	12
341	Peri-engraftment syndrome in allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2013, 48, 523-528.	1.3	34
342	Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment. <i>Bone Marrow Transplantation</i> , 2013, 48, 926-931.	1.3	45
343	Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin. <i>Bone Marrow Research</i> , 2013, 2013, 1-8.	1.7	10

#	ARTICLE	IF	CITATIONS
344	The significance of cytomegalovirus viremia at day 100 or more following allogeneic hematopoietic stem cell transplantation. <i>Clinical Transplantation</i> , 2013, 27, 510-516.	0.8	6
345	Early lymphocyte recovery predicts superior overall survival after unmanipulated haploidentical blood and marrow transplant for myelodysplastic syndrome and acute myeloid leukemia evolving from myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2013, 54, 2671-2677.	0.6	14
346	Ten-year follow-up of pediatric patients with non-hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. <i>Pediatric Blood and Cancer</i> , 2013, 60, 2018-2024.	0.8	38
347	Outcome and Challenges of Kidney Transplant in Patients with Sickle Cell Disease. <i>Journal of Transplantation</i> , 2013, 2013, 1-8.	0.3	16
348	Endocrinopathies after Allogeneic and Autologous Transplantation of Hematopoietic Stem Cells. <i>Scientific World Journal</i> , The, 2014, 2014, 1-13.	0.8	54
349	Comparison of reduced conditionings combining fludarabine with melphalan or 3-day busulfan in patients allografted for myeloid neoplasms. <i>International Journal of Hematology</i> , 2014, 100, 582-591.	0.7	5
350	Risk factors and organ involvement of chronic GVHD in Japan. <i>Bone Marrow Transplantation</i> , 2014, 49, 228-235.	1.3	50
351	Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults. <i>Acta Haematologica</i> , 2014, 132, 313-325.	0.7	14
352	High Level of Serum Soluble Interleukin-2 Receptor at Transplantation Predicts Poor Outcome of Allogeneic Stem Cell Transplantation for Adult T Cell Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 801-805.	2.0	23
353	Long-term outcome of HLA-haploidentical hematopoietic SCT without in vitro T-cell depletion for adult severe aplastic anemia after modified conditioning and supportive therapy. <i>Bone Marrow Transplantation</i> , 2014, 49, 519-524.	1.3	68
354	Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. , 2014, , CD009898.		2
355	Human herpesvirus 6 reactivation on the 30th day after allogeneic hematopoietic stem cell transplantation can predict grade 2-4 acute graft-versus-host disease. <i>Transplant Infectious Disease</i> , 2014, 16, 440-449.	0.7	35
356	Tolerability and Efficacy of Busulfan and Fludarabine As Allogeneic Pretransplant Conditioning Therapy in Acute Myeloid Leukemia: Comparison With Busulfan and Cyclophosphamide Regimen. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 493-500.	0.2	7
357	A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies. <i>Bone Marrow Transplantation</i> , 2014, 49, 955-960.	1.3	2
358	Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis. <i>International Journal of Hematology</i> , 2014, 100, 296-306.	0.7	10
359	Reduced-Intensity Allogeneic Transplantation Using Alemtuzumab from HLA-Matched Related, Unrelated, or Haploidentical Related Donors for Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 257-263.	2.0	15
360	A prospective feasibility study of primary prophylaxis against invasive fungal disease with voriconazole following umbilical cord blood transplantation with fludarabine-based conditioning. <i>International Journal of Hematology</i> , 2014, 99, 652-658.	0.7	8
361	Recipient Pretransplant Inosine Monophosphate Dehydrogenase Activity in Nonmyeloablative Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1544-1552.	2.0	7

#	ARTICLE	IF	CITATIONS
362	Mismatch on Glutathione S-Transferase T1 Increases the Risk of Graft-versus-Host Disease and Mortality after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1356-1362.	2.0	12
363	MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. <i>Blood</i> , 2014, 124, 1183-1191.	0.6	135
364	Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 1860-1867.	1.7	53
365	Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. , 2014, , CD009759.		2
366	Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2015, 50, 931-938.	1.3	8
367	A Safety and Efficacy Study of Medium-Dose Etoposide, Cyclophosphamide and Total Body Irradiation Conditioning Before Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia. <i>Transplantation Direct</i> , 2015, 1, 1-7.	0.8	12
368	Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. <i>The Cochrane Library</i> , 2015, , CD009759.	1.5	5
369	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. <i>Blood</i> , 2015, 126, 1033-1040.	0.6	565
370	Better allele-level matching improves transplant-related mortality after double cord blood transplantation. <i>Haematologica</i> , 2015, 100, 1361-1370.	1.7	32
371	Desialylation is associated with apoptosis and phagocytosis of platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT. <i>Journal of Hematology and Oncology</i> , 2015, 8, 116.	6.9	34
372	Impact of the source of hematopoietic stem cell in unrelated transplants: Comparison between 10/10, 9/10 HLA-matched donors and cord blood. <i>American Journal of Hematology</i> , 2015, 90, 897-903.	2.0	14
373	Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. <i>The Cochrane Library</i> , 2015, , CD009898.	1.5	6
374	T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells. <i>Bone Marrow Transplantation</i> , 2015, 50, S43-S50.	1.3	18
375	Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 85-96.	1.1	14
376	In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?. <i>Bone Marrow Transplantation</i> , 2015, 50, 1411-1415.	1.3	16
377	Reduced-Intensity Conditioning Combined with <sup>188</sup> Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1754-1760.	2.0	12
378	CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2106-2114.	2.0	49
379	Impact of HLA Mismatch Direction on the Outcome of Unrelated Bone Marrow Transplantation: A Retrospective Analysis from the Japan Society for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 305-311.	2.0	31

#	ARTICLE	IF	CITATIONS
380	Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1291-1298.	2.0	10
381	A modified busulfan and cyclophosphamide preparative regimen for allogeneic transplantation in myeloid malignancies. <i>International Journal of Clinical Pharmacy</i> , 2015, 37, 44-52.	1.0	9
382	Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2015, 50, 511-516.	1.3	6
383	Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapse. <i>Annals of Hematology</i> , 2015, 94, 1139-1148.	0.8	10
384	Older recipient age is paradoxically associated with a lower incidence of chronic GVHD in Thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with Thymoglobulin GVHD prophylaxis. <i>Bone Marrow Transplantation</i> , 2015, 50, 566-572.	1.3	3
385	State-of-the-art acute and chronic GVHD treatment. <i>International Journal of Hematology</i> , 2015, 101, 452-466.	0.7	72
386	Incidence and risk factors for ocular GVHD after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1459-1464.	1.3	53
387	Comparison of outcomes of idarubicin intensified TBI+CY and traditional TBI+CY conditioning regimen for high-risk acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A single center experience. <i>Leukemia Research</i> , 2015, 39, 1192-1200.	0.4	13
388	Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. <i>Leukemia and Lymphoma</i> , 2015, 56, 656-662.	0.6	32
389	Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time. <i>Bone Marrow Transplantation</i> , 2015, 50, 274-281.	1.3	18
390	Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 1058-1065.	0.6	19
391	The Changing Epidemiology of Bloodstream Infections and Resistance in Hematopoietic Stem Cell Transplantation Recipients. <i>Turkish Journal of Haematology</i> , 2016, 33, 216-222.	0.2	14
392	Genetic Background of Immune Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children. <i>Stem Cells International</i> , 2016, 2016, 1-6.	1.2	3
393	Early lymphocyte recovery predicts superior outcomes after unmanipulated haploidentical blood and marrow transplant for acute myeloid leukemia. <i>Clinical Transplantation</i> , 2016, 30, 954-958.	0.8	4
394	Effect of extracorporeal photopheresis on lung function decline for severe bronchiolitis obliterans syndrome following allogeneic stem cell transplantation. <i>Journal of Clinical Apheresis</i> , 2016, 31, 347-352.	0.7	22
395	Hematopoietic stem cell transplantation for people with sickle cell disease. <i>The Cochrane Library</i> , 2016, , CD007001.	1.5	14
396	Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older. <i>American Journal of Hematology</i> , 2016, 91, E284-92.	2.0	59
397	Successful Single-Lung Transplant for Severe Lung Graft-Versus-Host Disease Two Years After Sibling Allograft for Acute Lymphoblastic Leukemia: A Case Report. <i>Transplantation Proceedings</i> , 2016, 48, 3227-3230.	0.3	0

#	ARTICLE	IF	CITATIONS
398	Profile of Inflammation-Associated Proteins in Early Post-Transplant Samples of Patients After Allogeneic Hematopoietic Stem Cell Transplantation: a Preliminary Study. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2016, 64, 55-61.	1.0	3
399	Hematopoietic stem cell transplantation for T-cell large granular lymphocyte leukemia: a retrospective study of the European Society for Blood and Marrow Transplantation. <i>Leukemia</i> , 2016, 30, 1201-1204.	3.3	19
400	Allogeneic Hematopoietic Cell Transplantation for Leukemic Transformation Preceded by Philadelphia Chromosomeâ€“Negative Myeloproliferative Neoplasms: A Nationwide Survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2208-2213.	2.0	29
403	Haploidentical and Matched Sibling Donor Hematopoietic Cell Transplantation for Patients with HLA-Homozygous Haplotypes. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2031-2037.	2.0	5
404	Long-term outcomes of HLA-haploidentical stem cell transplantation based on an FBCA conditioning regimen compared with those of HLA-identical sibling stem cell transplantation for haematologic malignancies. <i>Bone Marrow Transplantation</i> , 2016, 51, 1470-1475.	1.3	8
405	Graft-versus-host disease in paediatric solid organ transplantation: A review of the literature. <i>Pediatric Transplantation</i> , 2016, 20, 607-618.	0.5	30
406	Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 744-751.	2.0	41
407	A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey. <i>International Journal of Hematology</i> , 2016, 103, 322-333.	0.7	13
408	Review of Cutaneous Graft-vs-Host Disease. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2016, 107, 183-193.	0.2	4
409	Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: A nationwide retrospective study. <i>Leukemia Research</i> , 2016, 41, 48-55.	0.4	25
410	AproximaciÃ³n a la enfermedad injerto contra huÃ©sped cutÃ¡nea. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2016, 107, 183-193.	0.2	14
411	Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 89-95.	1.3	30
412	Low Socioeconomic Status, Adverse Gene Expression Profiles, and Clinical Outcomes in Hematopoietic Stem Cell Transplant Recipients. <i>Clinical Cancer Research</i> , 2016, 22, 69-78.	3.2	63
413	Allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia who had central nervous system involvement: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation. <i>International Journal of Hematology</i> , 2017, 105, 805-811.	0.7	5
414	Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for younger patients with acute myeloid leukemia: a registry-based study. <i>Bone Marrow Transplantation</i> , 2017, 52, 818-824.	1.3	11
416	Cryopreserved CD34 + Cell Dose, but Not Total Nucleated Cell Dose, Influences Hematopoietic Recovery and Extensive Chronic Graft-versus-Host Disease after Single-Unit Cord Blood Transplantation in Adult Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1142-1150.	2.0	52
417	The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease. <i>Blood</i> , 2017, 129, 927-933.	0.6	153
418	Cardiovascular Risk Factors in Survivors of Childhood Hematopoietic Cell Transplantation Treated with Total Body Irradiation: A Longitudinal Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 475-482.	2.0	29



#	ARTICLE	IF	CITATIONS
419	Chronic Kidney Disease in Long-Term Survivors after Allogeneic Hematopoietic Stem Cell Transplantation: Retrospective Analysis at a Single Institute. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2159-2165.	2.0	23
420	Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2079-2087.	2.0	34
421	Impact of the presence of HLA 1-locus mismatch and the use of low-dose antithymocyte globulin in unrelated bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 1390-1398.	1.3	23
422	A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2088-2095.	2.0	9
423	Impact of Human Leukocyte Antigen Allele Mismatch in Unrelated Bone Marrow Transplantation with Reduced-Intensity Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 300-309.	2.0	12
424	Impact of graft-versus-host disease on outcomes after unrelated cord blood transplantation. <i>Leukemia</i> , 2017, 31, 663-668.	3.3	54
425	The Role of Anti-Thymocyte Globulin or Alemtuzumab-Based Serotherapy in the Prophylaxis and Management of Graft-Versus-Host Disease. <i>Biomedicines</i> , 2017, 5, 67.	1.4	16
426	Refractory Graft-Versus-Host Disease-Free, Relapse-Free Survival as an Accurate and Easy-to-Calculate Endpoint to Assess the Long-Term Transplant Success. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1521-1526.	2.0	10
427	Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1802-1807.	2.0	9
428	The Role of Allogeneic Transplantation for Multiple Myeloma in the Era of Novel Agents: A Study from the Japanese Society of Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1392-1398.	2.0	11
429	Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry. <i>Leukemia and Lymphoma</i> , 2018, 59, 85-96.	0.6	5
430	Graft-Versus-Host Disease and Graft-Versus-Leukemia Responses. , 2018, , 1650-1668.e10.		1
431	Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Soci�t� Francophone de Greffe de Moelle et de Th�rapie Cellulaire. <i>American Journal of Hematology</i> , 2018, 93, 416-423.	2.0	18
432	Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan. <i>Leukemia Research</i> , 2018, 75, 50-57.	0.4	21
433	Burden of cytomegalovirus disease in allogeneic hematopoietic cell transplant recipients: a national, matched cohort study in an inpatient setting. <i>Current Research in Translational Medicine</i> , 2018, 66, 95-101.	1.2	4
434	Acute Complications in Hematopoietic Stem Cell Transplantation and Cellular Immunotherapy. <i>Clinical Pediatric Emergency Medicine</i> , 2018, 19, 162-175.	0.4	0
435	Patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: trends in survival during the past two decades. <i>Bone Marrow Transplantation</i> , 2019, 54, 578-586.	1.3	17
436	Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation. <i>Hematological Oncology</i> , 2019, 37, 586-594.	0.8	8

#	ARTICLE	IF	CITATIONS
437	Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Cancer Science</i> , 2019, 110, 3255-3266.	1.7	32
438	A prospective observational study of immune reconstitution following transplantation with post-transplant reduced-dose cyclophosphamide from HLA-haploidentical donors. <i>Transplant International</i> , 2019, 32, 1322-1332.	0.8	24
439	Monocyte-predominant engraftment, cytokine levels and early transplant-related complications in pediatric hematopoietic stem cell recipients. <i>Cancer Medicine</i> , 2019, 8, 890-901.	1.3	4
440	Allogeneic hematopoietic cell transplantation for patients with a history of multiple relapses of acute myeloid leukemia. <i>Annals of Hematology</i> , 2019, 98, 2179-2186.	0.8	8
441	Unit selection for umbilical cord blood transplantation for adults with acute myeloid leukemia in complete remission: a Japanese experience. <i>Bone Marrow Transplantation</i> , 2019, 54, 1789-1798.	1.3	39
442	Red blood cell transfusion burden by day 30 predicts mortality in adults after single-unit cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1836-1846.	1.3	5
443	ABO blood type incompatibility lost the unfavorable impact on outcome in unrelated bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1676-1685.	1.3	10
444	Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndrome. <i>Annals of Hematology</i> , 2019, 98, 1367-1381.	0.8	13
445	Short-term clinical outcomes after HLA 1-locus mismatched uPBSCT are similar to that after HLA-matched uPBSCT and uBMT. <i>International Journal of Hematology</i> , 2019, 109, 684-693.	0.7	3
446	Impacts of post-transplantation cyclophosphamide treatment after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <i>Scientific Reports</i> , 2019, 9, 2046.	1.6	8
447	Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors. <i>Blood Advances</i> , 2019, 3, 105-115.	2.5	25
448	Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. <i>Blood Advances</i> , 2019, 3, 2454-2464.	2.5	12
449	HLA discrepancy between graft and host rather than that graft and first donor impact the second transplant outcome. <i>Haematologica</i> , 2019, 104, 1055-1061.	1.7	3
450	Prognostic impact of melphalan dose and total body irradiation use in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation with reduced-intensity conditioning. <i>Leukemia and Lymphoma</i> , 2019, 60, 1493-1502.	0.6	6
451	The Prognostic Impact of Pretransplantation Inflammatory and Nutritional Status in Adult Patients after Myeloablative Single Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 981-988.	2.0	13
452	Haploidentical transplantation outcomes are comparable with those obtained with identical human leukocyte antigen allogeneic transplantation in Chilean patients with benign and malignant hemopathies. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 40-45.	0.1	5
453	Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning. <i>International Journal of Hematology</i> , 2020, 111, 84-92.	0.7	9
454	Donor single nucleotide polymorphism in ACAT1 affects the incidence of graft-versus-host disease after bone marrow transplantation. <i>International Journal of Hematology</i> , 2020, 111, 112-119.	0.7	1

#	ARTICLE	IF	CITATIONS
455	Effects of Haplotype Matching on Outcomes after Adult Single-Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 509-518.	2.0	11
456	Time-Varying Effects of Graft Type on Outcomes for Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 307-315.	2.0	12
457	Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study. <i>Leukemia</i> , 2020, 34, 128-137.	3.3	36
458	The effect of graft-versus-host disease on outcomes after allogeneic stem cell transplantation for refractory lymphoblastic lymphoma in children and young adults. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28129.	0.8	5
459	Impact of HLA Allele Mismatch at HLA-A, -B, -C, and -DRB1 in Single Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 519-528.	2.0	34
460	Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia: A Report from the Japan Society for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 902-910.	2.0	16
461	Comparing the outcomes between TMLI and non-TMLI conditioning regimens for adult high-risk acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: a single-center experience. <i>Leukemia and Lymphoma</i> , 2020, 61, 2859-2867.	0.6	3
462	Programmed death 1 ligand (PD-L1) in solid cancers after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Nagasaki Transplant Group. <i>International Journal of Hematology</i> , 2020, 112, 524-534.	0.7	1
463	Patterns of Genital Examination and Vulvovaginal Graft-Versus-Host Disease in a Pediatric Post-Hematopoietic Stem Cell Transplant Population. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2020, 33, 658-666.	0.3	7
464	Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century. <i>Annals of Hematology</i> , 2020, 99, 1351-1360.	0.8	26
465	Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. <i>Blood Advances</i> , 2020, 4, 2073-2083.	2.5	39
466	Effect of graft-versus-host disease on outcomes after pediatric single cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1430-1437.	1.3	9
467	Long-term results of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia: a retrospective analysis of 10-year follow-up data. <i>Bone Marrow Transplantation</i> , 2020, 55, 2008-2016.	1.3	7
468	Impact of graft-versus-host disease and graft-versus-leukemia effect based on minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>British Journal of Haematology</i> , 2020, 190, 84-92.	1.2	13
469	Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 3367-3376.	0.8	69
470	Hematopoietic stem cell transplantation for people with sickle cell disease. <i>The Cochrane Library</i> , 2020, 2020, CD007001.	1.5	2
471	Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1784-1795.	1.3	17
472	Influence of HLA 1*3-locus mismatch and antithymocyte globulin administration in unrelated bone marrow transplantation. <i>Annals of Hematology</i> , 2020, 99, 1099-1110.	0.8	1

#	ARTICLE	IF	CITATIONS
473	Allogeneic hematopoietic cell transplantation efficacy in patients with Philadelphia chromosome-positive acute myeloid leukemia in complete remission. <i>Bone Marrow Transplantation</i> , 2021, 56, 232-242.	1.3	0
474	Prediction of Acute Graft versus Host Disease and Relapse by Endogenous Metabolomic Compounds in Patients Receiving Personalized Busulfan-Based Conditioning. <i>Journal of Proteome Research</i> , 2021, 20, 684-694.	1.8	6
475	Prognostic Impact of the Fractionation of Total Body Irradiation for Patients with Acute Myeloid Leukemia Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 185.e1-185.e6.	0.6	2
476	Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan. <i>Annals of Hematology</i> , 2021, 100, 1849-1861.	0.8	6
477	Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies. <i>Bone Marrow Transplantation</i> , 2021, 56, 1691-1699.	1.3	4
478	Prognostic factors in salvage transplantation for graft failure following allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2183-2193.	1.3	3
479	Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 334.e1-334.e11.	0.6	23
480	Early-Phase Peripheral Blood Eosinophilia Predicts Lower Overall and Non-Relapse Mortality After Single-Unit Cord Blood Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 336.e1-336.e9.	0.6	1
481	Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients. <i>Bone Marrow Transplantation</i> , 2021, 56, 2510-2517.	1.3	9
482	Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type. <i>Clinical Cancer Research</i> , 2021, 27, 4825-4835.	3.2	14
483	Prognostic impacts of peripheral blood erythroblasts after single-unit cord blood transplantation. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1437-1442.	0.7	0
484	Prognostic impact of the dosage of methotrexate combined with tacrolimus for graft-versus-host disease prophylaxis after cord blood transplantation. <i>International Journal of Hematology</i> , 2021, 114, 252-262.	0.7	1
485	Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor. <i>Frontiers in Medicine</i> , 2021, 8, 604085.	1.2	13
486	Are hematopoietic cell transplant recipients with Gram-negative bacteremia spending more time outpatient while on intravenous antibiotics? Addressing trends over 10 years at a single center. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 1786-1794.	1.3	1
487	Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2021, 62, 3411-3419.	0.6	0
488	Allogeneic Hematopoietic Cell Transplantation from Alternative Donors in Acute Myelogenous Leukemia: A Comparative Analysis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1005.e1-1005.e8.	0.6	1
489	Syngeneic hematopoietic stem cell transplantation for acute myeloid leukemia: a propensity score-matched analysis. <i>Blood Cancer Journal</i> , 2021, 11, 159.	2.8	2
490	Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas. <i>Leukemia and Lymphoma</i> , 2022, 63, 231-234.	0.6	0

#	ARTICLE	IF	CITATIONS
491	Donor-Host Lineage-Specific Chimerism Monitoring and Analysis in Pediatric Patients Following Allogeneic Stem Cell Transplantation: Influence of Pretransplantation Variables and Correlation with Post-Transplantation Outcomes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 780.e1-780.e14.	0.6	6
492	Long-term outcomes following the addition of granulocyte colony-stimulating factor-combined high-dose cytarabine to total body irradiation and cyclophosphamide conditioning in single-unit cord blood transplantation for myeloid malignancies. <i>Annals of Hematology</i> , 2022, 101, 177-189.	0.8	4
493	Impact of HLA disparity on the risk of overall mortality in patients with grade II-IV acute GVHD on behalf of the HLA Working Group of Japan Society for Hematopoietic Cell Transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2990-2996.	1.3	2
494	Total body irradiation-containing conditioning regimens without antithymocyte globulin in adults with aplastic anemia undergoing umbilical cord blood transplantation. <i>Annals of Hematology</i> , 2022, 101, 165-175.	0.8	1
495	T-Cell Depletion to Prevent Graft-vs-Host Disease. , 2004, , 431-451.		3
496	Acute Graft-vs-Host Disease. , 2004, , 159-184.		2
497	Cellular Therapy for Hematology Malignancies: Allogeneic Hematopoietic Stem Transplantation, Graft-Versus-Host Disease, and Graft Versus Leukemia Effects. , 2012, , 303-366.		1
498	Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2020, 55, 1272-1281.	1.3	7
499	Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT. <i>Bone Marrow Transplantation</i> , 2020, 55, 1317-1325.	1.3	14
500	MYCOPHENOLATE MOFETIL AND CYCLOSPORINE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS AFTER ALLOGENEIC BLOOD STEM CELL TRANSPLANTATION. <i>Transplantation</i> , 1999, 67, 499-504.	0.5	99
501	LUNG TRANSPLANTATION AFTER ALLOGENEIC MARROW TRANSPLANTATION IN PEDIATRIC PATIENTS. <i>Transplantation</i> , 2001, 72, 1986-1990.	0.5	34
502	The gut microbiota and graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2019, 129, 1808-1817.	3.9	67
503	Non-Myeloablative Transplantation. <i>Hematology American Society of Hematology Education Program</i> , 2002, 2002, 392-421.	0.9	45
504	Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. <i>Blood</i> , 2002, 100, 2235-2242.	0.6	57
505	Marrow Transplants From Unrelated Donors for Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 1997, 90, 1410-1414.	0.6	2
506	T-Cell-Depleted Allogeneic Bone Marrow Transplantation as Postremission Therapy for Acute Myelogenous Leukemia: Freedom From Relapse in the Absence of Graft-Versus-Host Disease. <i>Blood</i> , 1998, 91, 1083-1090.	0.6	2
507	Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. <i>Blood</i> , 2000, 96, 2055-2061.	0.6	5
508	High incidence of extensive chronic graft-versus-host disease in patients with the REG3A rs7588571 non-GG genotype. <i>PLoS ONE</i> , 2017, 12, e0185213.	1.1	6

#	ARTICLE	IF	CITATIONS
509	Meta-analysis of the actions of antithymocyte globulin in patients undergoing allogeneic hematopoietic cell transplantation. <i>Oncotarget</i> , 2017, 8, 10871-10882.	0.8	23
510	Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Graft-versus-host disease. <i>Einstein (Sao Paulo, Brazil)</i> , 2020, 18, eAE4799.	0.3	5
511	Current Preventions and Treatments of aGVHD: From Pharmacological Prophylaxis to Innovative Therapies. <i>Frontiers in Immunology</i> , 2020, 11, 607030.	2.2	14
512	Endoscopic diagnosis of cytomegalovirus gastritis after allogeneic hematopoietic stem cell transplantation. <i>World Journal of Gastroenterology</i> , 2010, 16, 2907.	1.4	15
513	A multicenter feasibility study of chronic graft-versus-host disease according to the National Institute of Health criteria. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2011, 33, 283-289.	0.7	7
514	The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. <i>Bone Marrow Transplantation</i> , 2022, 57, 57-64.	1.3	8
515	Dose Reduced Conditioning for Allogeneic Blood Stem Cell Transplantation from Sibling and Unrelated Donors in 51 Patients. <i>Hamatologie Und Bluttransfusion</i> , 2001, , 685-694.	0.0	0
516	Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2002, 99, 2255-2258.	0.6	8
517	Dose Reduced Conditioning for Allogeneic Blood Stem Cell Transplantation from Sibling and Unrelated Donors in 51 Patients. , 2003, , 59-73.		0
518	Pathophysiology of Lung Injury After Hematopoietic Stem Cell Transplantation. , 2004, , 271-295.		0
519	Chronic Graft-vs-Host Disease After Transplantation. , 2004, , 185-200.		0
520	Allogeneic stem cell transplantation. , 2004, , 513-537.		1
521	Late effects following allogeneic stem cell transplantation. , 2004, , 782-793.		0
522	HÄmatopoetische Stammzelltransplantation bei angeborenen Immundefekten. , 2005, , 523-531.		0
523	Lung Injury after Hematopoietic Stem Cell Transplantation. , 2008, , 495-536.		0
524	Chronic Graft-versus-Host Disease. , 2008, , 621-649.		0
526	Outcomes of Salvage Autologous Versus Allogeneic Hematopoietic Cell Transplantation for Relapsed Multiple Myeloma After Initial Autologous Hematopoietic Cell Transplantation. <i>Journal of Clinical Medicine Research</i> , 2013, 5, 174-84.	0.6	14
527	Therapeutic Application of Amniotic Fluid Stem Cells for Graft-Versus-Host Disease. , 2014, , 43-52.		0

#	ARTICLE	IF	CITATIONS
528	Marrow Transplantation: Current Results and Effect of Immunoglobulin Prophylaxis. , 1997, , 107-110.		0
529	Late effects of cancer therapy. Cancer Treatment and Research, 1997, 92, 343-375.	0.2	0
530	Marrow Transplants from Unrelated Donors for the Treatment of High-Risk Acute Leukemia. Hamatologie Und Bluttransfusion, 1998, , 1111-1124.	0.0	0
531	Late Gastrointestinal and Hepatic Effects. Pediatric Oncology, 2015, , 229-252.	0.5	0
532	Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients. Clinical Pediatric Hematology-Oncology, 2015, 22, 127-135.	0.0	0
533	Cutaneous Graft-Versus-Host Disease. , 2017, , 665-683.		0
534	Tumorablative conditioning regimen for haploidentical stem cell transplantation in 102 children with hematologic malignancies: a single-center experience. Oncotarget, 2017, 8, 113749-113757.	0.8	2
535	Retrospective Evaluation Of Children After Stem Cell Transplantation: Single Center Experience. Journal of Contemporary Medicine, 0, , .	0.1	0
537	Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation. Clinical and Experimental Immunology, 1994, 97 Suppl 1, 53-7.	1.1	3
538	The Relationship between STR-PCR Chimerism Analysis and Chronic GvHD Following Hematopoietic Stem Cell Transplantation. International Journal of Hematology-Oncology and Stem Cell Research, 2017, 11, 24-29.	0.3	2
539	Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia. Leukemia, 2022, 36, 1132-1138.	3.3	16
540	Disease-specific impact of anti-thymocyte globulin in allogeneic hematopoietic cell transplantation: a nationwide retrospective study on behalf of the JSTCT, transplant complications working group. Bone Marrow Transplantation, 2022, 57, 479-486.	1.3	5
541	Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia. Annals of Hematology, 2022, 101, 643-653.	0.8	6
542	Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors. Blood Advances, 2022, 6, 1895-1903.	2.5	5
543	Impact of HLA Epitope Matching on Outcomes After Unrelated Bone Marrow Transplantation. Frontiers in Immunology, 2022, 13, 811733.	2.2	2
544	Diagnosis and staging of ophthalmic manifestations of the graft-versus-host reaction after allogeneic hematopoietic stem cell transplantation. Ophthalmology Journal, 2021, 14, 91-102.	0.1	1
545	Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning. Blood Advances, 2022, 6, 2618-2627.	2.5	12
546	Single Cord Blood Transplantation Versus HLA-Haploidentical-related Donor Transplantation Using Posttransplant Cyclophosphamide in Patients With Hematological Malignancies. Transplantation, 2022, 106, 1279-1287.	0.5	4

#	ARTICLE	IF	CITATIONS
547	Comparison of Myeloablative and Nonmyeloablative Hematopoietic Stem Cell Transplantation for Treatment of Chronic Myeloid Leukemia. <i>International Journal of Hematology</i> , 2007, 86, 275-281.	0.7	6
548	Effect of Multiple HLA Locus Mismatches on Outcomes after Single Cord Blood Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 398.e1-398.e9.	0.6	6
549	Overcoming minimal residual disease using intensified conditioning with medium-dose etoposide, cyclophosphamide and total body irradiation in allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. <i>Cytotherapy</i> , 2022, 24, 954-961.	0.3	3
550	Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	16
551	Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients. <i>Cytotherapy</i> , 2022, 24, 1013-1025.	0.3	3
552	Outcomes of salvage haploidentical transplantation using posttransplant cyclophosphamide for graft failure following allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2022, 116, 744-753.	0.7	4
553	Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 681-693.	0.6	13
554	BONE MARROW TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES AND CANCER. <i>Radiologic Clinics of North America</i> , 1996, 16, 393-427.	0.9	0
555	Age and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia. <i>International Journal of Hematology</i> , 2023, 117, 398-408.	0.7	1
556	Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 0, , .	0.8	0